financetom
Business
financetom
/
Business
/
Finnair picks Embraer instead of Airbus for its narrow-body fleet renewal
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Finnair picks Embraer instead of Airbus for its narrow-body fleet renewal
Mar 23, 2026 12:19 AM

HELSINKI, March 23 (Reuters) - Finnair said

on Monday it will renew its European fleet with an order for 18

E195-E2 narrow-body aircraft from Brazilian manufacturer Embraer ( EMBJ )

, moving away from its current provider Airbus.

Finnair's choice deals a further blow to France's Airbus, after

the Brazilian Embraer's E2 outsold Airbus A220 three to one last

year. Finnair said it also plans to acquire up to 12 Airbus A320

or A321 from the used aircraft market.

"This is a highly versatile aircraft and one of the quietest

on the market," Chief Executive Turkka Kuusisto told Reuters.

"It will reduce our CO₂ emissions by 30 percent per

passenger carried. In addition to enabling us to operate

efficiently within Finland and widely across Europe, it also

supports our climate objectives," he added.

The Embraer ( EMBJ ) order includes options for 16 additional

aircraft and purchase rights for a further 12, Finnair said,

adding it had signed deals with RTX's Pratt & Whitney

for spare engines and maintenance services.

The airline, majority-owned by the Finnish state, has

navigated years of upheaval, first from the COVID-19 pandemic

and, since 2022, from the mutual airspace closures between

Russia and EU countries following Russia's invasion of Ukraine.

Embraer ( EMBJ ) has benefited from a global boom in demand for

regional jets as airlines catch up with fleet replacements set

aside during the pandemic, the planemaker's CEO Arjan Meijer

told Reuters in January.

Finnair last year said it urgently needed to replace 15 older

models from its narrow-body fleet of 29 Airbus planes and added

more new jets might be bought to meet growing demand.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Best Buy beats quarterly sales estimates on stable demand
Best Buy beats quarterly sales estimates on stable demand
Aug 28, 2025
Aug 28 (Reuters) - Best Buy ( BBY ) posted a surprise rise in second-quarter sales on Thursday, driven by strong online sales and a surge in demand for artificial intelligence-powered computers, mobile phones and other devices. However, shares fell 2% in premarket trading as the top U.S. electronics retailer maintained its annual sales and profit forecasts. The stock is...
Best Buy beats quarterly sales estimates on stable demand
Best Buy beats quarterly sales estimates on stable demand
Aug 28, 2025
(Reuters) -Best Buy ( BBY ) posted a surprise rise in second-quarter sales on Thursday, driven by strong online sales and a surge in demand for artificial intelligence-powered computers, mobile phones and other devices. However, shares fell 2% in premarket trading as the top U.S. electronics retailer maintained its annual sales and profit forecasts. The stock is down about 12%...
Malibu Boats Q4 sales rise 30.4%, beat estimates
Malibu Boats Q4 sales rise 30.4%, beat estimates
Aug 28, 2025
Overview * Malibu Boats ( MBUU ) Q4 net sales rise 30.4%, beating analyst expectations * Adjusted EPS for Q4 misses analyst estimates, per LSEG data * Adjusted EBITDA for Q4 misses analyst expectations, despite significant increase Outlook * Malibu anticipates fiscal 2026 net sales to be flat to down mid-single digits * Company expects fiscal 2026 Adjusted EBITDA margin...
Outlook Therapeutics Says FDA Needs Additional Efficacy Data for Eye Disease Drug Candidate; Shares Plunge Pre-Bell
Outlook Therapeutics Says FDA Needs Additional Efficacy Data for Eye Disease Drug Candidate; Shares Plunge Pre-Bell
Aug 28, 2025
07:06 AM EDT, 08/28/2025 (MT Newswires) -- Outlook Therapeutics ( OTLK ) said Thursday the US Food and Drug Administration has issued a complete response letter to its resubmitted biologics license application for ONS-5010 to treat wet age-related macular degeneration. The company said the regulator cited a lack of substantial evidence of effectiveness, noting the therapy failed to meet the...
Copyright 2023-2026 - www.financetom.com All Rights Reserved